Association of UBQ-8i polymorphism with Alzheimer's disease in Caucasians: a meta-analysis. (1st June 2015)

• Record Type: Journal Article
• Authors: Yue, Zhen; Wang, Sen; Yan, Weiping; Zhu, Fengyi
• Is Part Of: International journal of neuroscience. Volume 125:Number 6(2015:Jun.)
• Page Start: 395
• Page End: 401
• Publication Date: 2015-06-01
• Subjects: Nervous system -- Periodicals; 612.805
• DOI: 10.3109/00207454.2014.943369
• Languages: English
• ISSNs: 0020-7454

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <italic>Background:</italic> Several studies have reported an association between the UBQ-8i (rs12344615) polymorphism of the <italic>UBQLN1</italic> gene and risk of Alzheimer's disease (AD), but these findings remain controversial. In this study, a meta-analysis was carried out to investigate the relationship between UBQ-8i polymorphism and AD risk and a possible synergy with <italic>apolipoprotein E</italic> (<italic>APOE</italic>)<italic>ε4</italic> gene status. <italic>Methods:</italic> Case–control studies were selected from PubMed, Medline and Embase (Ovid) databases. The potential association was evaluated by odds ratios (ORs) with 95% confidence intervals (CIs). Data were analyzed with Stata version 11.0. <italic>Results:</italic> A total of 4679 AD cases and 9928 controls were included in the study. There was no evidence of heterogeneity between studies or publication bias in the meta-analysis. There were no significant differences among the examined genetic models. In the analysis stratified by age of onset, a significant association was detected in the late onset AD group under the allele (OR = 1.12, 95% CI: 1.01–1.24), heterozygote (OR = 1.15, 95% CI: 1.02–1.30) and dominant (OR = 1.13, 95% CI: 1.00–1–26) models. However, UBQ-8i polymorphism was not associated with a higher risk for AD among <italic>APOEε4</italic> carriers. <italic>Conclusion:</italic> The results suggest that UBQ-8i polymorphism may contribute to AD susceptibility, but does not synergize with <italic>APOEε4</italic> status to increase AD risk.</p> </abstract>